>>> Fed Vice Chair Stanley Fischer: Fed likely to raise rates before year end an

Fed Vice Chair Stanley Fischer: Fed likely to raise rates before year end and could be driven by a multiple of factors - comments in New York 
- after first rate increase, rate moves could be up or down
- not expecting a repeat of prior gradual rate increase campaigns
- current unemployment rate is near its natural level
- supplementary tools could help the Fed increase short term rates when appropriate

FT : Private equity’s big clear-out boosts SVG

Private equity’s big clear-out boosts SVG

A buoyant market for buyout firms selling off pre-crisis investments boosted returns for the listed British private equity investor SVG Capital last year, as disposals of companies including Hugo Boss and Freescale raised cash and lifted valuations.
SVG’s portfolio of private equity funds generated a total return of 10 per cent and a 14 per cent increase in its net asset value per share for the 13 months to the end of January, according to its annual results on Monday.

The group handed a record £330m in cash to shareholders, who invest in SVG as a tradeable proxy for the performance of buyout funds, including Permira, its largest holding.
The results were tempered by the euro’s slide versus sterling — total return was 17 per cent in local currencies — but they also show how a year of surging valuations on stock markets has resurrected investments that private equity once preferred to forget.
The increase in SVG’s NAV to 588p a share was driven by the doubling last year of the share price of Freescale, the US semiconductor company which has since been acquired by NXP for $16.7bn.
Permira invested in Freescale in 2006 as part of a private equity consortium. Waylaid by the financial crisis, the company’s value languished below its purchase price until last year.
“We’ve been waiting for a long time for that one,” said Lynn Fordham, SVG chief executive. “Freescale going above cost was a big thing.”
Sales by Permira of shares in Hugo Boss also drove nearly half of the £330m returned to shareholders, and the completion of its exit from the 2006 investment this month will provide further cash this year.
Spun out from Schroders’ private equity business nearly two decades ago, SVG has sought to overhaul its investment strategy in the past three years, including reducing its reliance on Permira.
The group’s 10 largest fund investments fell from four-fifths to two-thirds of its portfolio over the year. A quarter of the portfolio is in 30 investments — including European and US funds Cinven and Clayton Dubilier & Rice — added since 2012 in a £467m commitment of capital.
The group said it also changed its year end from December 31 to January 31 because it needed more time to collect and calculate the end of year valuation of its various investments.
SVG has returned £540m to shareholders since 2012, more than its market capitalisation before it announced its new strategy.
The flipside is that rising valuations are making it harder for buyout firms to find good deals. “We’re very careful whom we choose as managers: we’re quite cautious” at the moment, Ms Fordham said.

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: KSU -4.2%, FMSA -3.5%

Other news: MEIP -65.9% (announces top-line data from a randomized Phase II clinical study of Pracinostat in combination with azacitidine), IMMR -9.4% (announces settlement and license agreement With HTC Corporation (HTCKF) to resolve patent litigation), VRTX -7.1% (announces data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation), FINL -5.7% (unfavorable commentary on Friday's Mad Money), CERU -3.6% (appoints Chris Guiffre President and CEO), LULU -3% (still checking; worth noting several analysts out on name ahead of earnings this Thursday), GILD -2.4% (following reports of issues and a death related to its Harvoni Hep C drug taken in combination with amiodarone), SHPG -1.5% (may be down in symp with other bio/pharma names), GSK -1.4% (may be down in symp with other bio/pharma names), MNKD -1.1% (may be down in symp with other bio/pharma names), ARMH -1.1% (still checking), ABBV -0.7% (AbbVie (ABBV), which has a competing HCV drug Viekira with GILD), ACHN -0.5% (unfavorable commentary on Friday's Mad Money)

Analyst comments: NVDA -2.8% (downgraded to Sell from Neutral at Goldman), CCL -2.3% (downgraded to Hold at Deutsche Bank), OLN -1.8% (downgraded to Sell from Neutral at UBS), BIIB -1.8% (downgraded to Hold from Buy at Stifel), PRGO -1.6% (downgraded to Sector Perform at RBC Capital Mkts), NTAP -1.5% (downgraded to Neutral from Overweight at Piper Jaffray), EMC -1.1% (downgraded to Neutral from Overweight at Piper Jaffray)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: SVT +4.1%, BLRX +1.9%, DSKY +1.7%

M&A news: THC +4.8% (confirms that it and United Surgical Partners International will combine their ambulatory surgery and imaging centers in new JV; Tenet also announces purchase of Aspen Healthcare), SAN +1.5% (reports co plans to make bid for Novo Banco)

Other news: MCP +25% (60 Minutes reported on importance of rare earth elements), IMGN +22.4% (announces that Takeda (TKPYY) has licensed exclusive rights to use ImmunoGen's ADC technology to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets), FRSH +8.6% (favorable commentary on Friday's Mad Money), CANF +7.5% (signs multi-million dollar distribution agreement for CF101 in Canada with Cipher Pharmaceuticals (CPHR)), KMDA +6.1% (announces that the European Commission has designated its human intravenous Alpha-1 Antitrypsin as an orphan medicinal product to treat Graft-versus-host disease), NBG +4.5% (cont volatility surrounding Greece), CRNT +4.3% (announced that a Tier 1 mobile operator in Africa is investing approximately $4 million to expand its large scale Ceragon-based backbone network), BTN +4.2% (Issues statement in response to proxy contest), ESLT +1.3% (U.S. subsidiary awarded a $73.4 mln USMC IDIQ contract for Common Laser Range Finder), BLBD +1.1% (announces 92 Blue Bird propane-fueled school buses will power fleet of school vehicles in Colorado; also Hennessy Capital discloses 13.4% active stake in 13D filing), PAA +1.1% (Joint Venture with Delek Logistics to Build Caddo Pipeline)

Analyst comments: CAPN +9.9% (initiated with a Buy at Maxim Group), DVAX +5.9% (upgraded to Overweight from Neutral at JP Morgan; tgt raised to $36 from $15), GNW +5.7% (upgraded to Strong Buy from Outperform at Raymond James), NMM +5.3% (upgraded to Buy from Hold at Deutsche Bank), CYBR +3.6% (initiated with a Buy at BofA/Merrill), ITEK +3.5% (initiated with a Buy at Canaccord Genuity), SPLS +2.7% (upgraded to Buy from Neutral at UBS), AMH +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley), MSCC +0.9% (initiated with an Outperform at BMO Capital), TYC +0.8% (upgraded to Overweight at Barclays), AAPL +0.8% (target raised to $135 from $115 at Cowen)